GO
Loading...

FDA

More

  • March 13- Venaxis Inc said its appendicitis test correctly predicted results in 97 percent of patients in a clinical trial, sending its shares up 25 percent in premarket trade. The company said it expected to finalize its marketing application and submit it to the U.S. Food and Drug Administration in the next few weeks.

  • *Shares fall more than 6 percent after FDA sanction. The FDA has imposed a rash of regulatory sanctions on Indian generic makers in the last year, triggering concerns about the quality of the medicines supplied by the $14 billion industry to countries including the United States, the biggest market. "The FDA is becoming more stringent.

  • March 12- Geron Corp said the U.S. Food and Drug Administration ordered a halt to trials of its cancer drug imetelstat over concerns about potential liver damage, sending the company's shares plunging almost 60 percent before the bell.

  • March 11- Senomyx Inc said the U.S. Food and Drug Administration had declared that its Sweetmyx food flavoring was safe, paving the way for customers such as PepsiCo Inc to add it to drinks to reduce the use of sugar and sugar substitutes.

  • FDA says Senomyx sweetener enhancer safe; shares jump Tuesday, 11 Mar 2014 | 10:55 AM ET

    March 11- Senomyx Inc said the U.S. health regulator designated its Sweetmyx food flavoring safe, paving the way for customers such as PepsiCo Inc to add it in drinks to reduce the use of sugar or sugar substitutes.

  • Some medical experts and lawmakers are urging the FDA to reconsider its approval of the new narcotic painkiller Zohyrdo, reports CNBC's Sheila Dharmarajan.

  • March 7- The U.S. Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday.

  • March 7- The U.S. Food and Drug Administration has asked Regeneron and Sanofi to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday. U.S.-listed shares of France- based Sanofi were down 1 percent.

  • March 6- Endo International Plc said the U.S. Food and Drug Administration approved its thrice-rejected testosterone replacement therapy, Aveed, to treat male hypogonadism.

  • FDA approves Endo Health's testosterone drug Thursday, 6 Mar 2014 | 7:14 AM ET

    March 6- Endo Health Solutions Inc said the U.S. Food and Drug Administration approved its thrice-rejected testosterone drug, Aveed, to treat male hypogonadism. The health regulator rejected the drug last May, saying that Endo needed a better plan to manage the risks associated with the drug.

  • March 4- Oxygen Biotherapeutics Inc said the U.S. Food and Drug Administration had lifted an order imposed in 2008 suspending trials of its experimental brain injury drug, sending the company's shares up by more than a third in early trading.

  • March 4- Oxygen Biotherapeutics Inc said the U.S. Food and Drug Administration had lifted an order imposed in 2008 suspending trials of its experimental brain injury drug, sending the company's shares up by more than a third in early trading.

  • March 4- Oxygen Biotherapeutics Inc said the U.S. Food and Drug Administration had lifted an order suspending trials of its experimental brain injury drug, sending the company's shares up by more than a third in premarket trading.

  • WASHINGTON, Feb 28- Generic drugmakers are furiously campaigning against a proposed U.S. rule that would require them to change the prescribing information on their products if they receive new safety information, which they say would open them to product liability lawsuits.

  • Feb 28- A new federal program aims to standardize inspection procedures for pet food and farm animal feed produced in the United States, making them safer, the U.S. Food and Drug Administration said on Friday.

  • John Foraker, Annie's CEO, discusses why its consumers are interested in non-GMO products. "Lowering our guidance had nothing to do with genetically modified ingredients," he explains.

  • Annie's CEO: Our anti-GMO edge     Friday, 28 Feb 2014 | 11:51 AM ET

    The Food and Drug Administration announced it wants to revamp nutrition labels on foods. John Foraker, Annie's CEO, discusses how a label change might impact his business.

  • The opioid drug, manufactured by Zogenix Inc, contains a potent amount of an active ingredient that could be lethal to new patients and children and is not safer than other current pain drugs, the groups told the Food and Drug Administration. In December, attorneys general from 28 states also urged the FDA to reconsider its approval of the drug.

  • Discussing the regulations for affordable medicine, with Mylan CEO Heather Bresch. She also discusses growth strategies for the company.

  • Food label makeover     Thursday, 27 Feb 2014 | 2:50 PM ET

    The White House and the U.S. Food and Drug Administration is proposing to change nutrition facts labeling. Meme Roth, National Action Against Obesity president, and Katherine Mangu-Ward, Reason Magazine managing editor, share their opinions.

Most Popular Video

Wednesday, 16 Apr 2014 | 12:00 AM ET

GM unveils new models, hopes for strong sales this year After massive recalls, General Motors is pushing forward with new car models unveiled at the 2014 New York International Auto Show. CNBC's Phil LeBeau explains.

Friday, 11 Apr 2014 | 7:23 AM ET

Former Fed Chairman Ben Bernanke challenges Raghuram Rajan, Reserve Bank of India governor on his views about monetary policies, reports CNBC's Michelle Caruso-Cabrera.

Tuesday, 15 Apr 2014 | 5:40 PM ET

Jonathan Geller, BGR president and editor-in-chief, weighs in on the specifications for Amazon's newly announced 3-D smartphone.